Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial.

Saved in:
Bibliographic Details
Title: Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial.
Authors: Brandon R; Department of Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand., Jiang Y; Department of Statistics, Faculty of Sciences, The University of Auckland, Auckland, New Zealand.; National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand., Yeu RQ; Department of Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand., Tweedie-Cullen R; Department of Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand., Smallman K; Diabetes Foundation Aotearoa, Auckland, New Zealand., Doherty G; Tongan Health Society, Auckland, New Zealand., Macaskill-Smith KA; Ventures/Pinnacle Incorporated, Hamilton, New Zealand., Doran RJ; Ventures/Pinnacle Incorporated, Hamilton, New Zealand., Clark P; Ventures/Pinnacle Incorporated, Hamilton, New Zealand., Moffitt A; Procare Primary Health Organisation, Auckland, New Zealand., Merry T; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.; Discipline of Nutrition, University of Auckland, Auckland, New Zealand., Nehren N; Te Hiku Hauora, Northland District Health Board, Kaitaia, New Zealand., King F; Ngāti Porou Hauora, Tairāwhiti, New Zealand., Hindmarsh JH; Ngāti Porou Hauora, Tairāwhiti, New Zealand., Leask MP; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.; Department of Biochemistry, University of Otago, Dunedin, New Zealand.; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States., Merriman TR; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.; Department of Biochemistry, University of Otago, Dunedin, New Zealand.; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States., Orr-Walker B; Middlemore Clinical Trials, Auckland, New Zealand., Shepherd PR; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.; Department of Molecular Medicine and Pathology, School of Medical Sciences, The University of Auckland, Auckland, New Zealand., Paul R; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.; Department of Medicine, University of Waikato, Waikato, New Zealand., Murphy R; Department of Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.
Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Jan 09; Vol. 13, pp. 1091421. Date of Electronic Publication: 2023 Jan 09 (Print Publication: 2022).
Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-2392
DOI:10.3389/fendo.2022.1091421